The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 study of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, with gemcitabine/nab-paclitaxel (GnP) in first-line advanced pancreatic ductal adenocarcinoma (PDAC).
 
Devalingam Mahalingam
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; EMD Serono
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Eisai; Exelixis; Genentech
Research Funding - Merck KGaA; Oncolytics
 
Benedito A. Carneiro
Consulting or Advisory Role - EMD Serono; Foundation Medicine; G1 therapeutics; Tempus
Research Funding - Abbvie (Inst); Actuate Therapeutics (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Pfizer (Inst); Repare Therapeutics (Inst); Repare Therapeutics (Inst)
 
Howard Safran
No Relationships to Disclose
 
Steven Francis Powell
Consulting or Advisory Role - Bristol-Myers Squibb (Inst)
Research Funding - Actuate Therapeutics (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Incyte (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst); Vyriad (Inst)
 
Andrew L. Coveler
Consulting or Advisory Role - Abbvie; Halozyme; Merrimack; Seagen
Research Funding - AbGenomics International (Inst); Actuate Therapeutics (Inst); Amgen (Inst); Amgen (Inst); Genentech (Inst); Gilead Sciences (Inst); Halozyme (Inst); Immunomedics (Inst); Lilly (Inst); MedImmune (Inst); Newlink Genetics (Inst); Novocure (Inst); Onconova Therapeutics (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); XBiotech (Inst)
Travel, Accommodations, Expenses - Abbvie; Halozyme
 
Elizabeth J. Davis
Honoraria - MJH Life Sciences
Consulting or Advisory Role - Deciphera
Speakers' Bureau - Physicans' Education Resource
Research Funding - Actuate Therapeutics (Inst); Bristol-Myers Squibb (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); TopAlliance BioSciences Inc (Inst)
 
Andres Cervantes
Consulting or Advisory Role - Amgen (Inst); BeiGene (Inst); BMS (Inst); Merck Serono (Inst)
Research Funding - Abbvie (Inst); Activate Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); Astellas Pharma (Inst); BeiGene (Inst); Bioncotech (Inst); Boehringer Ingelheim (Inst); Debiopharm Group (Inst); F. Hoffmann LaRoche (Inst); FibroGen (Inst); Genmab (Inst); Janssen Research & Development (Inst); MedImmune (Inst); Menarini (Inst); Novartis (Inst); Puma Biotechnology (Inst); Symphogen (Inst); Taiho Pharmaceutical (Inst); Transgene (Inst); WntResearch (Inst)
 
Vaibhav Sahai
Consulting or Advisory Role - AstraZeneca; Celgene; GlaxoSmithKline; Halozyme; Histosonics; Incyte; Ipsen; Klus Pharma; Newlink Genetics; QED Therapeutics; Rafael Pharmaceuticals
Research Funding - Agios (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); Exelixis (Inst); FibroGen (Inst); Halozyme (Inst); Incyte (Inst); Ipsen (Inst); MedImmune (Inst); Pancreatic Cancer Action Network (Inst); Rafael Pharmaceuticals (Inst); Relay Therapeutics (Inst); Syros Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - ASCO; FibroGen; FibroGen
 
Neeltje Steeghs
Consulting or Advisory Role - AIMM Therapeutics (Inst); Boehringer Ingelheim (Inst); Ellipses Pharma (Inst)
Research Funding - AB Science (Inst); Abbvie (Inst); Actuate Therapeutics (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Cantargia AB (Inst); Cytovation (Inst); Deciphera (Inst); Genentech (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Incyte (Inst); InteRNA (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Marisol Huerta
No Relationships to Disclose
 
Jordan Berlin
Consulting or Advisory Role - Bayer Health; Clovis Oncology; insmed; ipsen; Mirati Therapeutics; qed therapeutics
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Atreca (Inst); Bayer (Inst); boston biomedical (Inst); Bristol-Myers Squibb/Celgene (Inst); Day One Biopharmaceuticals (Inst); Dragonfly Therapeutics (Inst); EMD Serono (Inst); I-MAB (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); pfizer (Inst); PsiOxus Therapeutics (Inst)
Travel, Accommodations, Expenses - boston Biomedical
Other Relationship - Karyopharm Therapeutics; novocure; Pancreatic Cancer Action Network
 
Mary Frances Mulcahy
Honoraria - Boston Scientific
Consulting or Advisory Role - Boston Scientific
Research Funding - BTG
 
Francis J. Giles
Employment - Actuate Therapeutics
Stock and Other Ownership Interests - Actuate Therapeutics
 
Ludimila Cavalcante
Employment - Actuate Therapeutics
Stock and Other Ownership Interests - Actuate Therapeutics
 
Anwaar Saeed
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Exelixis; Five Prime Therapeutics; Pfizer
Speakers' Bureau - Daiichi Sankyo/Astra Zeneca
Research Funding - Actuate Therapeutics (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo/UCB Japan (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); KAHR Medical (Inst); Merck Sharp & Dohme (Inst); Seagen (Inst)